{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:40:18Z","timestamp":1648744818282},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.bone.2008.12.013","type":"journal-article","created":{"date-parts":[[2008,12,25]],"date-time":"2008-12-25T10:41:37Z","timestamp":1230201697000},"page":"634-638","source":"Crossref","is-referenced-by-count":4,"title":["Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone"],"prefix":"10.1016","volume":"44","author":[{"given":"Vit","family":"Zikan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan J.","family":"Stepan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2008.12.013_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2008.12.013_bib2","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","article-title":"Catabolic effects of continuous human PTH (1\u201338) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation","volume":"142","author":"Ma","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2008.12.013_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","article-title":"Osteoclast-derived activity in the coupling of bone formation to resorption","volume":"11","author":"Martin","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bone.2008.12.013_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/117727190800300005","article-title":"Marker of bone resorption in acute response to exogenous or endogenous parathyroid hormone","volume":"3","author":"Zik\u00e1n","year":"2008","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.bone.2008.12.013_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","article-title":"Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women","volume":"13","author":"Cosman","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib7","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2008.12.013_bib8","first-page":"S26","article-title":"Patients previously treated with risedronate demonstrate greater responsiveness to teriparatide than those previously treated with alendronate: the OPTAMISE study","volume":"22","author":"Miller","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2008.12.013_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2008.12.013_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib12","first-page":"S27","article-title":"Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: the OPTAMISE study","volume":"22","author":"Delmas","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib13","first-page":"S6","article-title":"Histomorphometric changes by teriparatide in alendronate pre-treated women with osteoporosis","volume":"23","author":"Stepan","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1359\/jbmr.2000.15.5.863","article-title":"In vivo demonstration that human parathyroid hormone 1\u201338 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene","volume":"15","author":"Onyia","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02441175","article-title":"Time-related changes in the ultrastructure of osteoclasts after injection of parathyroid hormone in young rats","volume":"27","author":"Holtrop","year":"1979","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2008.12.013_bib16","first-page":"1535","article-title":"Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1\u201334): kinetics and biochemical response in estrogenized osteoporotic patients","volume":"77","author":"Lindsay","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2008.12.013_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0009-9236(97)90169-7","article-title":"Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1\u201384)] in healthy postmenopausal volunteers","volume":"61","author":"Schwietert","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2008.12.013_bib18","first-page":"S197","article-title":"Calcitonin attenuates the anabolic effect of PTH in young rats","volume":"21","author":"Gooi","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00223-008-9104-y","article-title":"Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro","volume":"82","author":"Idris","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2008.12.013_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF01623309","article-title":"Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion","volume":"5","author":"Landman","year":"1995","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.bone.2008.12.013_bib21","first-page":"939","article-title":"Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women","volume":"78","author":"Cosman","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2008.12.013_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2265.2001.01263.x","article-title":"Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis","volume":"54","author":"Oleksik","year":"2001","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.bone.2008.12.013_bib23","first-page":"S322","article-title":"Rapid and robust biochemical response to teriparatide therapy for osteoporosis","volume":"22","author":"Eastell","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2008.12.013_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.1976.tb01947.x","article-title":"Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency","volume":"5","author":"Rude","year":"1976","journal-title":"Clin. Endocrinol. (Oxf)"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208009575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208009575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T18:01:52Z","timestamp":1558029712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328208009575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S8756328208009575"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2008.12.013","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}